Bayer Eyes Indications Beyond BlueRock's Initial Focus With $240m-Plus Buyout

 
• By Mandy Jackson

Bayer will acquire the 40.8% of BlueRock that it doesn't already own as the firm's largest investor via a $225m series A round in 2016. A clinical trial for BlueRock's Parkinson's disease candidate is expected to begin later this year.

Business partners hands on top of each other symbolizing companionship
Bayer will oversee the company's operations, but maintain BlueRock's entrepreneurial nature. • Source: Shutterstock

More from Deals

More from Business